Biomarkers in prostate cancer surveillance and screening: past, present, and future

Autor: K. Clint Cary, Mathew R. Cooperberg

Publikováno v: Therapeutic Advances in Urology, Vol 5 (2013)

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease. Current clinical practice has been driven largely by the utilization of prostate-specific antig

Externí odkaz: https://doaj.org/article/028326662fd943c69711d8e6e8420309

Prostate cancer mortality and metastasis under different biopsy frequencies in North American active surveillance cohorts

Autor: Sigrid Carlsson, Anna Bill-Axelson, Bruce J. Trock, Jane M. Lange, David F. Penson, Daniel W. Lin, Mathew R. Cooperberg, Ruth B. Etzioni, Janet E. Cowan, Aaron A. Laviana, Laurence Klotz, Peter R. Carroll, Lisa F. Newcomb, H. Ballentine Carter

Publikováno v: Cancer. 126(3)

Background Active surveillance (AS) is an accepted means of managing low-risk prostate cancer. Because of the rarity of downstream events, data from existing AS cohorts cannot yet address how differences in surveillance intensity affect metastasis an

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8828067d42e6c5daed2a6c18172dfa26
https://pubmed.ncbi.nlm.nih.gov/32401651

Biomarkers in prostate cancer surveillance and screening: past, present, and future

Autor: K. Clinton Cary, Mathew R. Cooperberg

Publikováno v: Therapeutic advances in urology, vol 5, iss 6
Therapeutic Advances in Urology, Vol 5 (2013)

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication have revolutionized the diagnosis and management of the disease. Current clinical practice has been driven largely by the utilization of prostate-specific antig

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a680f10780c8b1ba86e228bda9bcd7cf
https://europepmc.org/articles/PMC3825107/

Prostate Cancer Screening and the Goldilocks Principle: How Much Is Just Right?

Autor: Faiena I; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Holden S; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Cooperberg MR; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Holden S; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Soule HR; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Simons JW; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Morgan TM; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Penson DF; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Morgans AK; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL., Hussain M; Izak Faiena and Stuart Holden, David Geffen School of Medicine at UCLA, Los Angeles, CA; Mathew R. Cooperberg, University of California, San Francisco, San Francisco, CA; Stuart Holden, Howard R. Soule, and Jonathan W. Simons, Prostate Cancer Foundation, Santa Monica, CA; Todd M. Morgan, University of Michigan, Ann Arbor, MI; David F. Penson, Vanderbilt University Medical Center, Nashville, TN; and Alicia K. Morgans and Maha Hussain, Northwestern University, Chicago, IL.

Publikováno v: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2018 Apr 01; Vol. 36 (10), pp. 937-941. Date of Electronic Publication: 2018 Feb 05.